key: cord-0787044-r4urgkee
authors: Burel, E.; Colson, P.; Lagier, J.-C.; LEVASSEUR, A.; Bedotto, M.; Lavrard, P.; Fournier, P.-E.; LA SCOLA, B.; Raoult, D.
title: Sequential appearance and isolation of a SARS-CoV-2 recombinant between two major SARS-CoV-2 variants in a chronically infected immunocompromised patient
date: 2022-03-23
journal: nan
DOI: 10.1101/2022.03.21.22272673
sha: 7dcc7afb659fe4f59f99eebde82b2d6883413c59
doc_id: 787044
cord_uid: r4urgkee

Genetic recombination is a major evolutionary mechanism among RNA viruses, and it is common in coronaviruses, including those infecting humans. A few SARS-CoV-2 recombinants have been reported to date whose genome harbored combinations of mutations from different mutants or variants, but a single patient sample was analyzed, and the virus was not isolated. Here, we report the gradual creation of a hybrid genome of B.1.160 and Alpha variants in a lymphoma patient chronically infected for 14 months, and we isolated the recombinant virus. The hybrid genome was obtained by next-generation sequencing, and recombination sites were confirmed by PCR. This consisted of a parental B.1.160 backbone interspersed with two fragments, including the spike gene, from an Alpha variant. Analysis of seven sequential samples from the patient decoded the recombination steps, including the initial infection with a B.1.160 variant, then a concurrent infection with this variant and an Alpha variant, the generation of hybrid genomes, and eventually the emergence of a predominant recombinant virus isolated at the end of the patient follow-up. This case exemplifies the recombination process of SARS-CoV-2 in real life, and it calls for intensifying genomic surveillance in patients coinfected with different SARS-CoV-2 variants, and more generally with several RNA viruses, as this may lead to the creation of new viruses.

CoV-2 RNA remained detectable by qPCR on most nasopharyngeal samples collected until 76 patient's death. qPCR was negative at Month 5 of diagnosis but positive when re-tested at 77

Month 7, and then only transiently negative for ≤3 days. 78

After 14 months of infection, we identified a virus whose genome was a hybrid of two 80 known variants, B. Figure 1; Figure 2) . 85

This hybrid genome was obtained from the respiratory samples by next-generation 86 sequencing, as previously described [27] . In addition, the hybrid virus was isolated in culture, 87 as previously described [33] . The hybrid genome sequence consisted of a B.1. We believe that this observation, which sheds light on the recombination mecha-nism 143 of RNA viruses, is significant, and to our knowledge this is the first one describing, through 144 the analysis of sequential samples over more than a year, the creation of a re-combinant 145 SARS-CoV-2 and the isolation of the recombinant virus in culture. Sixteen interlineage 146 recombinants between the Alpha variant and non-Alpha viruses were reported in 2021 in the 147 UK, of 279,000 genomes analyzed [8] . In addition, 1,175 (0.2%) pu-tative recombinant 148 genomes were identified among 537,360 genomes, and it was reported that up to 5% of 149 SARS-CoV-2 that circulated in the USA and UK might be recombinants [18] . Moreover, the 150 number of cases of detection of recombinant genomes is growing [10, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Recently, 151 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Supplementary Table S1). 206

Sequencing of reverse-transcription-PCR-targeted regions: Extraction of the RNA 208 samples was carried out using the EZ1 Virus kit with the EZ1 Advanced XL instrument 209 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.21.22272673 doi: medRxiv preprint mix of 24 µL of Klenow Fragment DNA polymerase (New England Biolabs, Beverly, MA, 231 USA), 66 µL of nuclease-free water, 45 µL of NEB Buffer 2 (New England Biolabs), and 15 232 µL of dNTPs working solution produced with 10 µL of each dNTP at a 100 mM 233 concentration, and 60 µL of nuclease-free water (New England Biolabs). This mix was kept at 234 37°C for one hour. A purification step consisted in adding 450 µL of magnetic CleanNGS 235 beads for a 1:1 volume ratio (CleanNA, Waddinxveen, the Netherlands) then incubating for 5 236 min in a magnetic support, and washing with 1,000 µL of ethanol at 70%, before elution of 237 beads in 50 µL of Tris EDTA 1X with centrifugation for 10 min at 300 rpm at room 238 temperature. Subsequently, DNA library was prepared with the DNA ligation sequencing kit 239 SQK-LSK109 (Oxford Nanopore Technologies Ltd.), and next-generation sequencing was 240 performed with the Nanopore technology on a PromethION instrument (Oxford Nanopore 241 Technologies Ltd. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

The authors have no conflicts of interest to declare relative to the present study. Didier 283

Raoult was a consultant for the Hitachi High-Technologies Corporation, Tokyo, Japan from 284 2018 to 2020. He is a scientific board member of the Eurofins company and a founder of 285 a microbial culture company (Culture Top). Funding sources had no role in the design and 286 con-duct of the study, the collection, management, analysis, and interpretation of the data, and 287 the preparation, review, or approval of the manuscript. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

2) were amplified using the following 52 primers (in 5'-3' orientation): Forward: TTCAACCTGAAGAA-GAGCAA; reverse: 53 TGGCATTGTAACAAGAGTTT

C4543U) signature mutations. For the amplicon cor-responding to positions 24

U26876C and G28975C) mutations, and 24% were hybrids harboring 60 Alpha mutation G24914C and B.1.160 mutation G28975C

Metagenomic sequencing: Next-generation sequencing was also carried out using a 62 metagenomic approach with the Nanopore technology on a GridION instrument

Nanopore Technologies Ltd.) to attempt obtaining long sequence reads and detect addi-tional 64 reads that are hybrids of the B.1.160 and Alpha variants

Viral RNA load as determined by cell

SARS-CoV-2 qPCR performed on nasopharyngeal samples was positive between 17